Oilfield services company Core Laboratories (NYSE: CLB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 4.3% year on year to $124.6 million. Its non-GAAP profit of $0.11 per share was 26.9% above analysts’ consensus estimates.

Is now the time to buy Core Laboratories? Find out by accessing our full research report, it’s free.

Company Overview

With roots dating back to the first commercial oil boom, Core Laboratories (NYSE: CLB) analyzes rock and fluid samples from oil and gas reservoirs to help energy companies optimize production and recovery.

Revenue Growth

A company’s long-term performance can give signals about its business quality. Even a bad business, especially in a cyclical industry, can shine for a year or so, but a top-tier one should exhibit resilience through cycles. Regrettably, Core Laboratories’s sales grew at a weak 3.1% compounded annual growth rate over the last five years. This fell short of our benchmark for the energy upstream and integrated energy sector and is a tough starting point for our analysis.

Energy cycles can be long enough that a single five-year period can still reflect one price environment, which is why an additional, decade-long view can help capture through-cycle performance. Core Laboratories’s performance shows it grew in the past five-year but relinquished its gains over the last ten years, as its revenue fell by 2.7% annually.

This quarter, Core Laboratories missed Wall Street’s estimates and reported a rather uninspiring 4.3% year-on-year revenue decline, generating $124.6 million of revenue.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted EBITDA Margin

Core Laboratories was profitable over the last five years but held back by its large cost base. Its average EBITDA margin of 13.9% was among the worst in the energy upstream and integrated energy sector.

Analyzing the trend in its profitability, Core Laboratories’s EBITDA margin might have fluctuated slightly but has generally stayed the same over the last year, meaning it will take a fundamental shift in the business model to change.

This quarter, Core Laboratories generated an EBITDA margin profit margin of 11.1%, down 2.9 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. This adjusted EBITDA beat Wall Street’s estimates by 18.1%.

Cash Is King

As mentioned above, adjusted EBITDA ignores capital structure and drilling expenditure decisions. These are two huge aspects of an Energy producer, so in order to understand a comprehensive picture of business quality, an investor needs to account for these. Said differently, adjusted EBITDA margins could be solid but free cash flow is abysmal because decline rates of the asset are extreme and the drilling is expensive. Free cash flow tells you about not only the economics of the production that has happened but how much it costs to stay in business as well (further drilling or extraction).

Core Laboratories has shown weak cash profitability relative to peers over the last five years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 4.3%, below what we’d expect for an upstream and integrated energy business.

The level of free cash flow is important, but its durability across cycles is just as critical. Consistent margins are far more valuable than volatile swings driven by commodity prices.

Core Laboratories’s ratio of quarterly free cash flow volatility to WTI crude price volatility over the past five years was 7.7 (lower is better), indicating reasonable insulation from commodity swings.

You may be asking why we wait until the free cash flow line to perform this stability analysis versus commodity prices. Why not compare revenue or EBITDA to WTI Crude prices in the case of Core Laboratories? Because what ultimately matters is not how much revenue or profit you earn when prices are high but how much cash you can generate when prices are low. Free cash flow is the superior metric because it includes everything from hedging prowess to growth and maintenance capex to management behavior during good times and bad.

Core Laboratories’s free cash flow clocked in at $3.12 million in Q2, equivalent to a 2.5% margin. The company’s cash profitability regressed as it was 4.9 percentage points lower than in the same quarter last year, prompting us to pay closer attention. Short-term fluctuations typically aren’t a big deal because investment needs can be seasonal, but we’ll be watching to see if the trend extrapolates into future quarters.

Key Takeaways from Core Laboratories’s Q2 Results

It was good to see Core Laboratories beat analysts’ EPS expectations this quarter. On the other hand, its revenue slightly missed. Overall, this print had some positives. The market seemed to be hoping for more, and the stock traded down 4.2% to $9.45 immediately after reporting.

Is Core Laboratories an attractive investment opportunity right now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).